Sedana Medical appoints Johannes Doll as new CEO

Sedana Medical’s (publ) (SEDANA: FN Stockholm) Board of Directors has appointed Johannes Doll as the company’s new CEO. Johannes Doll will take office no later than November 1, 2021, succeeding Christer Ahlberg, who, as announced previously, will leave his position. The Board of Directors has appointed Sedana Medical's Commercial Director Jens Lindberg as Acting CEO from June 1.

Johannes Doll is currently Chief Commercial Officer (EVP and Chief Commercial Officer) at Orexo, where he worked for almost eight years. Doll has about 16 years of experience from the life science industry, including as a consultant for nearly eight years at McKinsey & Company.

“Johannes Doll has the qualities needed to take Sedana Medical to the next level. Now that we are facing commercialization in Europe and establishment in the USA, Johannes' drive and previous experience from having established Orexo in the USA will be a great and important asset for the company,” said Thomas Eklund, Chairman of the Board of Sedana Medical.

“I have followed Sedana Medical for a while and am impressed by the journey the company has made. It feels very honoring and fun to join the company in this exciting next phase. I am convinced that inhaled sedation can make a tremendous difference for intensive care patients around the world. Therefore, I look forward to working with such a passionate and qualified team to establish Sedaconda as the standard of care in ICUs across our launch markets and subsequently bring this therapy to the important US market,” said Johannes Doll, Chief Commercial Officer at Orexo and incoming CEO of Sedana Medical.

For additional information, please contact:

Thomas Eklund, Chairman of the Board, Sedana Medical
Mobile: +46 70 824 20 25
E-mail: thomas.eklund@investorab.com

Christer Ahlberg, CEO, Sedana Medical
Mobile: +46 70 675 33 30
E-mail: christer.ahlberg@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on May 12, 2021 at 08.00 a.m. (CET).

About Sedana Medical

Sedana Medical AB (publ) develops and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the drug candidate Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company has applied for market approval in Europe for Sedaconda and expects an approval in the second half of 2021.

Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Globally, seven to eight million patients are estimated to be sedated in intensive care due to mechanical ventilation, evenly distributed between the US, Europe, and Asia. These patients are on average sedated three to four days. Sedana Medical estimates the total market potential to SEK 20-30 billion. Three years after marketing approval in Europe, Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated processes to obtain market approval in the US in 2024 and in markets outside the EU.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics and Spain as well as external distributors in other parts of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.